|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0362 SEK | +0.56% |
|
+14.56% | -21.30% |
Eurocine Vaccines AB (publ) reported earnings results for the fourth quarter ended June 30, 2023. For the fourth quarter, the company reported net loss was SEK 3.09 million compared to SEK 5.19 million a year ago. Basic loss per share from continuing operations was SEK 0.111 compared to SEK 0.302 a year ago.
Diluted loss per share from continuing operations was SEK 0.111 compared to SEK 0.302 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -21.30% | 850K | |
| +38.36% | 52.73B | |
| +38.73% | 39B | |
| -8.63% | 38.52B | |
| +25.46% | 30.38B | |
| -11.17% | 26.39B | |
| +11.44% | 26.08B | |
| +45.09% | 14.15B | |
| +32.93% | 12.6B | |
| -5.30% | 11.51B |
EUROCINE VACCINES AB 
